Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The …

The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of
mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal …

Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological
malignancies characterized by dysplasia, ineffective hematopoiesis and a variable risk of …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Enhancer of zeste homologue 2 (EZH2), the catalytic subunit of Polycomb repressive
complex 2 (PRC2), has attracted broad research attention in the past few years because of …

Polycomb group (PcG) proteins are epigenetic regulators of transcription that have key roles
in stem-cell identity, differentiation and disease. Mechanistically, they function within …

Cancer arises as a consequence of cumulative disruptions to cellular growth control with
Darwinian selection for those heritable changes that provide the greatest clonal advantage …